Can we count your visit with Google Analytics? No ads, no profiles. Details
CRSP
USHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: $CRSP is the listed pure-play on CRISPR/Cas9 therapeutic editing, with Casgevy now approved in US/EU/UK/Saudi/Bahrain for SCD + TDT - the first-ever CRISPR gene edit medicine. Vertex ($VRTX) owns 60% of Casgevy economics and books revenue; $CRSP recognizes 40% net profit/loss share plus milestones.
Roughly $1.9B cash gives multi-year runway through 2027+ at current burn.
(1) Casgevy ramp inflecting - ~50 authorized treatment centers globally, ex-US reimbursement expanding 2026, addressable pop ~32k SCD + ~5k TDT in commercial geos; (2) allogeneic CAR-T (CTX112 in CD19 lymphoma, CTX131 in solid tumors) is the differentiated off-the-shelf bet vs autologous incumbents; (3) in vivo lipid program (CTX310 ANGPTL3, CTX320 LPA) is the platform-validation shot at the $VERV/$NTLA addressable cardiovascular pool; (4) cash + $VRTX cost-share shields dilution risk vs $EDIT/$BEAM/$NTLA.
(1) Casgevy uptake is structurally slow - myeloablative conditioning, $2.2M list, 6-12mo cell-collection-to-infusion cycle caps revenue trajectory; (2) base editing ($BEAM, $VERV) and prime editing ($PRME) may obsolete first-gen Cas9 cutting in 5-10yr; (3) CAR-T allogeneic field has serial setbacks (rejection, persistence) and $CRSP competes with $ALLO, $CRBU, $FATE-class peers; (4) single-product commercial concentration - any Casgevy safety signal is binary; (5) cash burn of ~$300M/yr against pre-profit P&L.
It reads our $CRSP data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.